Open Access

Erratum to: Risk of cardiovascular events among patients with HIV treated with atazanavircontaining regimens: a retrospective cohort study

  • Lisa Rosenblatt1,
  • Amanda M. Farr2Email author,
  • Ella T. Nkhoma3,
  • James K. Nelson4,
  • Corey Ritchings5 and
  • Stephen S. Johnston6
BMC Infectious DiseasesBMC series – open, inclusive and trusted201616:547

https://doi.org/10.1186/s12879-016-1903-6

Received: 27 September 2016

Accepted: 5 October 2016

Published: 7 October 2016

The original article was published in BMC Infectious Diseases 2016 16:492

Erratum

n.b. The errors and associated corrections described in this document concerning the original manuscript were accountable to the production department handling this manuscript, and thus are no fault of the authors of this paper. Additionally, the online manuscript has now been updated with these corrections accordingly.

In the original publication of this article [1], Fig. 3 had [VALUE] (0.72, 2.23) where it should have said 1.27 (0.72, 2.23). This has now been updated in the original article.
Fig. 3

Propensity-score-weighted hazard ratios for composite CV event during as-treated follow-up period: Secondary comparisons. CI confidence interval, CV cardiovascular, DRV darunavir, HR hazard ratio, PI protease inhibitor

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Bristol-Myers Squibb
(2)
Truven Health Analytics
(3)
Bristol-Myers Squibb
(4)
Truven Health Analytics
(5)
Bristol-Myers Squibb
(6)
Truven Health Analytics

References

  1. Rosenblatt L, et al. Risk of cardiovascular events among patients with HIV treated with atazanavircontaining regimens: a retrospective cohort study. BMC Infect Dis. 2016;16:492. doi:10.1186/s12879-016-1827-1.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement